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Abstract
Background: The potential pathogenesis between the presence and severity of chronic cerebrospinal venous
insufficiency (CCSVI) and its relation to clinical and imaging outcomes in brain parenchyma of multiple sclerosis
(MS) patients has not yet been elucidated. The aim of the study was to investigate the relationship between CCSVI,
and altered brain parenchyma venous vasculature visibility (VVV) on susceptibility-weighted imaging (SWI) in
patients with MS and in sex- and age-matched healthy controls (HC).
Methods: 59 MS patients, 41 relapsing-remitting and 18 secondary-progressive, and 33 HC were imaged on a 3T
GE scanner using pre- and post-contrast SWI venography. The presence and severity of CCSVI was determined
using extra-cranial and trans-cranial Doppler criteria. Apparent total venous volume (ATVV), venous intracranial
fraction (VIF) and average distance-from-vein (DFV) were calculated for various vein mean diameter categories: < .3
mm, .3-.6 mm, .6-.9 mm and > .9 mm.
Results: CCSVI criteria were fulfilled in 79.7% of MS patients and 18.2% of HC (p < .0001). Patients with MS showed
decreased overall ATVV, ATVV of veins with a diameter < .3 mm, and increased DFV compared to HC (all p <
.0001). Subjects diagnosed with CCSVI had significantly increased DFV (p < .0001), decreased overall ATVV and
ATVV of veins with a diameter < .3 mm (p < .003) compared to subjects without CCSVI. The severity of CCSVI was
significantly related to decreased VVV in MS (p < .0001) on pre- and post-contrast SWI, but not in HC.
Conclusions: MS patients with higher number of venous stenoses, indicative of CCSVI severity, showed
significantly decreased venous vasculature in the brain parenchyma. The pathogenesis of these findings has to be
further investigated, but they suggest that reduced metabolism and morphological changes of venous vasculature
may be taking place in patients with MS.
Background
Multiple sclerosis (MS) is considered a chronic, autoim-
mune, inflammatory disease of the central nervous system
(CNS) characterized by inflammation, demyelination, axo-
nal loss, and neurodegeneration [1].
Thin, linear periventricular white matter (WM) lesions
(Dawson’s fingers) present in the initial stages of MS are
often oriented around the long axis of central veins [2].
Histopathological studies have confirmed the close rela-
tionship between inflammatory MS lesions and venous
cerebral microvasculature, suggesting that the primary
inflammatory process in MS regionalizes around blood
vessels, with acute lesions showing lymphocytic perivas-
cular infiltration, hypercellularity, macrophage infiltra-
tion and intra-macrophage myelin debris [3].
Early MR venography (MRV) studies suggest that a
substantial number of MS lesions are crossed by well
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defined central veins [4]. These findings have been con-
firmed and extended by recent ultra-high-field 7T MRI
studies which showed that a majority of MS lesions are
associated with centrally coursing veins [5-7]. Close
examination revealed well defined central veins sur-
rounded by subtle abnormalities in signal intensities in a
strict perivenous fashion, with vascular wall involvement
[7,8].
Susceptibility-weighted imaging (SWI) venography can
directly image cerebral veins using deoxyhemoglobin as
an intrinsic contrast agent and, therefore, allows direct
and non-invasive assessment of venous blood oxygena-
tion saturation and visualization of the venous struc-
tures [9]. A recent pre-contrast SWI venography study
showed significantly reduced periventricular WM
venous vasculature visibility (VVV) in relapsing-remit-
ting (RR) MS patients as compared to healthy control
(HC) subjects [10].
The hypothesis that MS might be related to venous
pathology has been considered in the past [3,11-13].
Recently, a condition called chronic cerebrospinal
venous insufficiency (CCSVI) has been proposed and
reported with high frequency in MS [14,15]. CCSVI is
described as a vascular condition characterized by
anomalies of the main extra-cranial cerebrospinal
venous routes that interfere with normal blood outflow
of brain parenchyma in patients with MS [14-16]. The
pathogenesis between the presence and severity of
CCSVI and its relation to clinical and imaging outcomes
in brain parenchyma of MS patients has not yet been
elucidated. In two recent pilot studies, by using perfu-
sion-weighted imaging (PWI) and cerebrospinal fluid
(CSF) imaging, we showed that there are drainage pro-
blems in patients with MS associated with presence and
severity of CCSVI [17,18].
Therefore, the aim of this study was to extend our
preliminary results by investigating the relationship
between the presence and severity of CCSVI and altered
VVV in the brain parenchyma on pre- and post-contrast
SWI venography in patients with MS and in HC.
Methods
This study was part of the Combined Trans-cranial and
Extra-cranial Venous Doppler (CTEVD) study [19] that
investigated the prevalence of CCSVI in patients with
MS, clinically isolated syndrome (CIS), other neurologi-
cal diseases (OND), and healthy controls (HC), using
specific proposed Doppler criteria [14].
Fifty-nine (59) consecutive MS patients [41 RR and 18
secondary-progressive (SP)], and 33 age- and sex-
matched consecutive HC were enrolled in this sub-
study. Inclusion criteria were: RR or secondary-progres-
sive (SP) disease course for MS patients, [20] age 18 to
65 years, Expanded Disability Status Scale (EDSS) [21] 0
to 6.5, and undergoing MRI scan with SWI venography.
Exclusion criteria were: presence of relapse and steroid
treatment in the 30 days preceding study entry for all
patients, pre-existing medical conditions known to be
associated with brain pathology (e.g., cerebrovascular
disease, positive history of alcohol abuse, etc.), contrain-
dication for having a contrast agent injected for MRI
examination, history of cerebral congenital vascular mal-
formations, or pregnancy.
Participants underwent a clinical and MRI examina-
tion and trans-cranial and extra-cranial Doppler scans
of the head and neck. Doppler personnel were blinded
to the subjects’ status [19]. In particular, subjects were
specifically instructed not to reveal their disease status
during the Doppler examination. OND and CIS patients
were not part of this CTEVD SWI venography sub-
study, but were used as part of the overall population to
ensure blinding in the CTEVD study. The MRI evalua-
tors were completely blinded to subject’s disease, clinical
and CCSVI status.
The study was approved by the local Institutional
Review Board and informed consent was obtained from
all subjects.
Doppler evaluation
The Doppler exam was performed using Esaote-Bio-
sound MyLabGOLD25 ultrasound machine equipped
with 2.5 and 7.5-10 MHz transducers and motorized
chair capable of tilting from 0° to 90°. All study exami-
nations were performed by the same Doppler technolo-
gist. We examined Doppler parameters that detect 5
anomalous venous hemodynamic (VH) criteria affecting
cerebrospinal venous return, as previously described
[14]. These include: 1) reflux in the IJV and/or in the
VV assessed in both sitting and supine postures, 2)
reflux in the deep cerebral veins (DCV), 3) B-mode
detection of annuli, webs, septa, flaps or stenosis in the
IJV, 4) absence of an ECD signal in the IJV and/or in
the VV, even after forced deep breaths, and 5) presence
of a negative difference in the cross sectional area of the
IJV. More specific information is provided elsewhere
[19].
Each subject was assigned a total VH criteria score
which was calculated by counting the number of criteria
that the subject fulfilled. A subject was considered
CCSVI-positive, if ≥2 VH criteria were fulfilled, as pre-
viously proposed [14]. We also calculated the venous
hemodynamic insufficiency severity score (VHISS) [18].
The overall VHISS score is defined as a weighted sum
of the scores contributed by each individual VH criter-
ion. The formula for VHISS calculations was: VHISS =
VHISS1 + VHISS2 + VHISS3 + VHISS4 + VHISS5. The
VHISS score is an ordinal measure of the overall extent
and number of VH flow pattern anomalies, with a
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higher value of VHISS indicating a greater severity of
VH flow pattern anomalies. The minimum possible
VHISS value is 0 and the maximum 16.
MRI acquisition and analysis
All subjects were examined on a 3 Tesla GE Signa
Excite HD 12.0 Twin Speed 8-channel head coil scanner
(General Electric, Milwaukee, WI).
SWI data was collected in all patients using a 3-
Dimensional (3D) flow-compensated GRE (Gradient
Recalled Echo) sequence with 64 locs/slab, 2 mm
thick, a 512 × 192 matrix, FOV = 25.6 cm × 19.2 cm
(512 × 256 matrix with in plane phase FOV = 0.75),
for an in-plane resolution of 0.5 mm × 1 mm. Other
acquisition parameters were: flip angle FA = 12, echo
and repetition times (TE and TR) TE/TR = 22/40 ms,
for an acquisition time AT = 8:46 min:sec. k-space
data, as saved by the scanner (p-files) was saved and
transferred to an offline Linux workstation for post
processing using in-house developed software written
in Matlab (MathWorks Inc.). Forty-eight of the 59
(81.4%) MS patients and 7 of 33 (21.1%) HC enrolled
in the study obtained a second SWI scan after a single
dose intravenous bolus of 0.1 mMol/Kg Gadolinium
(Gd)-DTPA 10 min after injection. In order to test
reproducibility and obtain preliminary data on our pre-
and post-contrast experiment in HC, it was originally
decided that 20-25% of the HC cohort be included in
the contrast study. Additional MRI sequences acquired
included 2D multi-planar dual fast spin-echo (FSE)
proton density (PD) and T2-weighted image (WI),
Fluid-Attenuated Inversion-Recovery (FLAIR), 3D high
resolution (HIRES) T1-WI using a fast spoiled gradient
echo (FSPGR) with magnetization-prepared inversion
recovery (IR) pulse and spin echo (SE) T1-WI both
with and without a single dose intravenous bolus of
0.1 mMol/Kg Gd-DTPA 5 min after injection (in 48
MS patients). The relevant parameters were as follows:
for dual FSE PD/T2, echo and repetition times (TE
and TR) TE1/TE2/TR = 9/98/5300 ms, flip angle (FA)
= 90°, echo train length ETL = 14; for FLAIR, TE/TI/
TR = 120/2100/8500 ms (inversion time, TI), FA =
90°, ETL = 24; for SE T1-WI, TE/TR = 16/600 ms, FA
= 90; for 3D HIRES T1-WI, TE/TI/TR = 2.8/900/5.9
ms, FA = 10°. The 3D HIRES T1-WI scan was used
for brain volume segmentation.
SWI reconstruction
The k-space data, as saved by the scanner, include a
preliminary zero filling in the z-direction. This is a stan-
dard feature of the sequence as implemented by the
manufacturer and is not modifiable at the level of the
graphical interface of the scanner. Data for each channel
was reconstructed by zero-filling each slab location
(slice) to 768 × 576, to produce images with an interpo-
lated resolution of 0.33 mm × 0.33 mm. To ensure
proper composition of multi-channel data for the mag-
nitude and phase images, a channel re-centering and
normalization process was employed, as previously
described [22,23]. Following channel recombination, the
magnitude image was processed using the non-para-
metric non-uniform intensity normalization program N3
[23,24]. Phase images were high-pass filtered using a
192 × 144 Hanning window for vein analysis, as sug-
gested by Haacke et al. [25] The high-pass filtered phase
image was used to generate a phase mask, as previously
described [23,25]. SWI images were obtained by multi-
plying the phase mask four times onto the inhomogene-
ity-corrected magnitude image. SWI venograms were
generated by performing a minimum Intensity Projec-
tion (mIP) over 5 2-mm thick sections and moving the
mIP stack by one slice at a time.
Vein extraction
Quantification of SWI venous blood voxels was per-
formed by extracting the venous structures of the brain
from pre- and post-contrast SWI data using an in-
house-developed segmentation method. The main com-
ponent of the method is the vesselness filter described
by Sato et al., [26] based on the second order informa-
tion from the SWI mIP, represented by the Hessian
matrix (the 3 × 3 matrix generated by the second deri-
vatives of the image intensities in three spatial direc-
tions). By analyzing the eigenvalues (lj) of the Hessian,
a likeliness function was defined to distinguish tubular
structures (vessels) from non-tubular structures (e.g.,
background noise, brain parenchyma, cerebrospinal
fluid). The Hessian is calculated at a particular spatial
scale that is varied to detect vessels of different dia-
meters. The eigenvalues (lj) of the Hessian, sorted by
increasing magnitude (|l1| < |l2| < |l3|), describe the
local second order structure in an image; for instance, if
l2 and l3 have a high value and l1 is low, it means that
the image intensity is constant or almost constant in a
single direction only and changing rapidly in perpendi-
cular directions, indicative of a tubular-like structure.
The likeliness function was constructed to enhance dark
tubular structures based on the eigenvalues and three
tuning parameters: (a) defining the scale (s), varied to
detect vessels of different diameter, (b) defining the
“level of vesselness” (a1), quantitatively specifying the
qualitative relation |l1| < < |l2| & |l3| characterizing
tubular structures (Figure 1), and (c) restoring vessel
continuity in fragmented parts (a2), where a higher
noise level might result in fragmenting the curvilinear
structures (Equation 1).
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The values chosen for the aforementioned parameters
were driven by those suggested by Sato et al., [26] as
they are tuned to the size of the structures of interest
and the image voxel size: 0.2 < s < 2, a1 = 0.5, a2 = 2.
One of the primary results of the paper by Sato et al.
[26] is showing the stability of the results with respect
to variations of these parameters around the reported
values.
Multi-scale filter approach segmentation steps are
represented in Figure 2. To assess the performance of
the vesselness filter with respect to signal to noise ratio
(SNR), the filter output was thresholded and overlaid
onto the original mIP data for visual inspection of the
segmentation process. Visual comparison with mIP
images confirmed that the line-filter had high detection
sensitivity with respect to small vessels, vessel continu-
ity, and the reduction of noise and artifacts, both pre-
and post-contrast injection. Note that, in order to obtain
optimal 3D projections of the datasets, the brain was
extracted (i.e., the skull was removed) by using the FSL-
brain extraction tool [27].
Apparent total venous volume (ATVV) measurement
for total vein vasculature was performed in milliliters
(ml) and the relative venous intracranial fraction (VIF)
was calculated by normalization with respect to the
intracranial volume as calculated by the FSL-brain
extraction tool, to correct for head size (Figure 3).
The size of individual veins was measured in mm,
and 4 groups were created according to their mean
Figure 1 Three-dimensional scatter plot of the eigenvalues of the Hessian matrix. The voxels belonging to linear structures are those for
which |l2| and |l3| are negative while |l1| is close to zero, resulting in the cluster in the bottom part of the plot.
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diameters: < .3 mm, .3-.6 mm, .6-.9 mm and > .9 mm.
Classification of the vessels in the four size classes
was performed by iterative erosion and dilation of the
vein extraction map slice by slice. As a first step, an
upsampled map was generated, doubling the number
of voxels in each direction in the axial plane (from
768 × 576 to 1536 × 1152); consequently, at each
iteration of the erosion and dilation process the ves-
sels size was reduced or increased, respectively, by a
voxel unit. By eroding and dilating the vessel mask
and taking the difference from the original vessel
mask, the linear structures that were a size smaller
than the original voxel size (< .3 mm) were left (Figure
3). Iterating this process up to 4 times produced clas-
sification of the linear structures in the diameter
classes < .3 mm, .3-.6 mm, .6-.9 mm and > .9 mm. At
every iteration, a size filter was applied in order to
avoid discontinuities in every size-class map due to
local inhomogeneities or higher noise level. As a mIP
image is used for the underlying processing, the vein
volume measurements, while correlating with the
actual vein volume in the brain, tend to increase vein
visibility in the brain over other structures. In particu-
lar, this approach enhances the visibility of smaller
veins over larger ones, as the former are projected
over multiple neighboring slices, while the latter tend
to be projected on themselves.
Each vein extraction map was verified by an experi-
enced neuroimager, and any misclassifications were
manually corrected.
As a last step, starting from the vein extraction maps,
voxel-wise minimum distance from vein (DFV) maps
were calculated, defined as the distance of each voxel
from the closest voxel classified as belonging to a vein;
in such maps longer distance indicates lower local vein
density (Figure 3). The average value of this map was
calculated over the whole brain, providing an average-
distance-from-vein score.
Interclass correlation coefficient (ICC) values for all
vein extraction indices were calculated on a set of 5 HC
and 5 MS patients that were scanned twice over a one
week period, both on pre- and post-contrast SWI
images.
SWI pre- and post-contrast experiment
It has been reported that SWI venography can be
further enhanced through the injection of a contrast
agent, producing increased sensitivity and image quality
[28,29]. The amount of accumulated phase, and there-
fore contrast, is proportional to the concentration of the
contrast agent [25]. We previously reported in a pilot
study that contrast-enhanced SWI significantly increases
the number and volume of signal hypointensities on
SWI venography in T2 lesions and in normal appearing
WM (Figure 4) [30]. In order to investigate the SWI
VVV parameter differences between pre- and post-con-
trast SWI additionally, 48 MS patients and 7 HC under-
went both sequences in this study.
Lesion and atrophy analyses
T2 hyperintense, T1 hypointense and gadolinium lesion
volumes (LVs) were outlined using a semi-automated
edge-detection contouring-thresholding technique [31].
Global and regional brain atrophy was determined
with corrections for T1-hypointensity misclassification
using an in-house developed in-painting program, on
the 3D T1 weighted scans using SIENAX version 2.6., as
described previously [32].
Statistical analyses
Statistical analyses were performed using the Statistical
Package for Social Sciences (SPSS, version 16.0). For
descriptive statistics and estimates of CCSVI prevalence
and its severity, t-tests, Fisher’s exact tests and the
Mann-Whitney rank sum U-test were used. Given that
not all VVV indices were normally distributed, we
employed non-parametric statistics. SWI venography
differences between groups were assessed using the
Mann-Whitney rank sum U-test. Differences between
Figure 2 Multi-scale filter approach segmentation steps are
presented by: a) recovery of line structures of various widths,
b) Hessian eigenvalues (i.e., linear intensity minima) removal of
the effects of non-linear structures and recovery of the original
structures as described by Sato et al., [26]c) removal of the
effects of non-uniformity of contrast material, noise and
artifacts, and d) 3-dimensionality
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Figure 3 The images display minimum projection (mIP) (horizontal upper row), apparent total venous volume (ATVV) (horizontal
middle upper row), ATVV with a diameter < .3 mm (horizontal middle lower row) and average distance from voxel (DFV) map
(horizontal lower row) for a healthy control (HC) (vertical left column), relapsing-remitting (RR) (vertical middle column) and
secondary progressive (SP) (vertical right column) multiple sclerosis patients. The images of ATVV and ATVV with a diameter < .3 mm
display the differences between HC, RR and SP MS patients [please note decreased ATVV (represented in light blue for ATVV and light green for
ATVV with a diameter < .3 mm)] especially in the ventricular, periventricular white matter, deep gray matter and cortical structures between HC
and MS patients, but no difference between RR and SP MS patients. The DFV maps show the differences between HC, RR and SP MS patients
(please note that the green color represents distance closer to the veins, whereas the yellow and orange colors represent longer distance to the
veins). RR and SP MS show more yellow and orange color compared to HC.
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Figure 4 Contrast enhanced susceptibility weighted imaging (SWI) increases detection of signal hypointensities on SWI venography in
patient with multiple sclerosis, in T2 lesions and normal appearing white matter [30]. Presented are pre-contrast (left), single dose post-
contrast (middle) and triple dose post-contrast (right) images. The rows represent: a) high-pass filtered SWI, b) SWI phase mask, c) magnitude
image multiplied 6 times by the phase mask, and d) minimum Intensity Projection image over 13 slices. Larger number and better defined
signal hypointesities are detected with single and triple dose post-contrast SWI compared to pre-contrast SWI.
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pre- and post-contrast SWI VVV measures in individual
MS patients were assessed using the Wilcoxon signed
rank test. Correlation analysis between severity of
CCSVI (VHISS) and pre- and post-contrast VVV para-
meters was performed using the Spearman rank correla-
tion coefficient. The primary null hypothesis was that
there is no association between CCSVI and MRI brain
parenchyma vein pathology. As a robust test of the
hypothesis that does not assume a relationship between
CCSVI and brain parenchyma vein pathology, we exam-
ined differences in MRI variables in the entire cohort of
subjects with and without CCSVI. If significance was
found, we performed the same comparison in individual
diagnostic subgroups and MS disease subtypes. Due to
multiple comparisons, only a nominal two-tailed p-value
< .01 was considered statistically significant.
Results
Demographic and clinical characteristics
Table 1 shows demographic, clinical and conventional
MRI characteristics of MS patients and HC. The median
number of days between Doppler and MRI examination
was 3. There were no age or sex differences between
MS patients and HC. As expected, the SP patients were
older, had longer disease duration and higher EDSS (p <
.0001). There were no significant demographic and clini-
cal differences between those who participated in the
SWI venography portion of the CTEVD study and those
who did not. There were no significant age, sex, disease
duration or conventional MRI characteristics differences
between the 48 MS patients and 7 HC who obtained
pre- or post-contrast SWI scans and the entire study
cohort. Of the 59 MS patients participating in the study,
56 were on disease-modifying therapy.
Scan-rescan dataset
ICC was slightly higher for the post-contrast SWI seg-
mentation VVV measures than for the pre-contrast
measures (Table 2). All VVV measures showed high
ICC values and were significant (p < .003). The highest
ICC were shown for the ATVV (.0.891) with vein sizes
> .6 mm being most reproducible. The VIF and DFV
ICC values ranged between 0.738 and 0.815.
CCSVI status assessment
All subjects had the 5 VH criteria assessed. Table 3
shows the CCSVI classifications by disease group and by
disease subtype. Prevalence of CCSVI was significantly
higher in MS patients compared to HC (p < .0001). The
measure of CCSVI severity (VHISS) was significantly
higher in MS patients compared to HC (p < .0001).
There was a higher prevalence of CCSVI in SP com-
pared to RRMS patients, but this difference did not
reach significance.
Vein vasculature visibility assessment
Table 4 shows quantitative assessment of brain parench-
yma pre- and post-contrast VVV according to disease
group and disease subtype. Patients with MS showed
decreased ATVV, ATVV of veins with a diameter < .3
mm and increased DVF (all p < .0001). There was also a
trend for lower VIF in MS patients (p = .049). Similar
pre- and post-contrast VVV values were detected in 48
MS patients who underwent both pre- and post-contrast
Table 1 Demographic and clinical characteristics in multiple sclerosis patients and healthy controls.
MS
(n = 59)
HC
(n = 33)
p RR
(n = 41)
SP
(n = 18)
p
Female gender, n (%) 43 (72.9) 20 (60.6) NS 28 (68.2) 15 (83.3) NS
Age in years, mean (SD) 44.6 (11) 41.3 (11.1) NS 40.5 (9.6) 53.8 (8.1) < .0001
Age at onset, mean (SD) 30.9 (9.8) —— — 30.6 (8.6) 31.7 (12.3) NS
Disease duration, mean (SD) 13.3 (10) — — 9.5 (5.7) 21.9 (12) < .0001
Expanded Disability Status Scale, mean (SD) median 3.2 (1) 2.5 — — 2.1 (0.9) 2.0 5.9 (1.1) 6.0 < .0001
T2 lesion volume, mean (SD) 12.8 (15.2) 2.3 (2.5) < .0001 8.9 (7.7) 21.9 (23) .0014
T1 lesion volume, mean (SD) 2.5 (6.5) — — 1.3 (2.8) 5.5 (10.6) .016
Gadolinium lesion volume, mean (SD) 0.07 (0.4) — — 0.1 (0.5) 0.01 (0.04) NS
Normalized brain volume, mean (SD) 1545.1 (107.3) 1642.4 (81.8) < .0001 1575.2 (94.5) 1476.4 (105.3) .002
Normalized gray matter volume, mean (SD) 828
(97.2)
882.4 (112.8) .022 855.8
(93.5)
764.7
74.5)
< .0001
Normalized white matter volume, mean (SD) 717.1
(68.5)
725.6
(72.6)
.018 719.5
(73)
711.7 (58.3) NS
MS - Multiple Sclerosis; HC - Healthy Controls; RR - Relapsing-Remitting; SP - Secondary Progressive; EDSS - Expanded Disability Status Scale; NS - non significant
All volumes are expressed in milliliters.
The differences between the study groups were tested using the chi-square, Student’s t-test and the Mann-Whitney rank sum test.
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SWI. However, in 7 HC who underwent pre- and post-
contrast SWI, significantly increased ATVV and ATVV
of veins were found, as well as DFV on post-contrast
scans. Increased ATVV occurred in veins with a dia-
meter < .3 mm and a trend for increased ATVV of
veins occurred in veins with a diameter < .3-.6 mm and
.6-.9 mm.
RRMS patients showed a trend for decreased pre-con-
trast ATVV, ATVV of veins with a diameter < .3 mm
and VIF compared to SPMS (all p < .06). Similar post-
contrast VVV values were found in 32 RR and 14 SP
MS patients who underwent both pre- and post-contrast
SWI (Table 4).
Presence of CCSVI and vein vasculature visibility
assessment
Table 5 shows quantitative brain parenchyma VVV in
MS patients and HC, according to CCSVI status on pre-
contrast SWI. Subjects diagnosed with CCSVI had sig-
nificantly increased DFV (p < .0001), decreased ATVV
and ATVV of veins with a diameter < .3 mm (p < .003)
compared to subjects without CCSVI. There was also a
trend for lower VIF (p = .044).
When only MS patients were investigated, significantly
increased DFV (p = .01) and a trend for decreased VIF
(p < .084) were found in subjects with CCSVI compared
to subjects without CCSVI on pre-contrast SWI. These
differences were more pronounced in RRMS subjects,
who showed significantly increased DFV (p = .009) and
a trend for lower VIF (p = .07). Similar post-contrast
VVV differences between MS patients with and without
CCSVI were found in 48 MS patients. Significantly
increased DFV (1.28 vs. 1, p = .01) and a trend for
decreased VIF (.061 vs. .066, p = .09) were found in MS
patients with CCSVI compared to subjects without
CCSVI.
No significant differences were observed between sub-
jects with and without CCSVI in HC.
No significant differences were observed between sub-
jects with and without CCSVI for other MRI measures.
Severity of CCSVI and vein vasculature visibility and other
MRI measurement assessments
Table 6 and Figure 5 show the association between
severity of CCSVI and quantitative assessment of brain
parenchyma VVV on pre- and post-contrast SWI. In
MS patients as a group, all quantitative brain parench-
yma venous vascular indices, reflecting increased
damage of venous vasculature, were significantly related
to higher VHISS (p < .0001) on both pre- and post-con-
trast images. The association was particularly strong in
RR, but not significant in SP MS patients alone.
No significant relationship was observed in HC
between VHISS and VVV indices.
Discussion
This is the first study to investigate the association
between the presence and severity of CCSVI and venous
vasculature in the brain parenchyma on SWI venogra-
phy in patients with MS and in HC. There are three
main findings in this study: 1) first, by examining only
brain parenchyma VVV, we found that MS patients are
compromised compared to HC. The novelty of our SWI
approach using pre- and post-contrast SWI venography
experiment is that its suggests that the reduced venous
visibility in brain parenchyma of MS patients is not only
the result of reduced metabolism, but may be affected
by possible morphological changes in venous vascula-
ture. This was not shown previously by using post-con-
trast SWI venography and only one previous study [10]
showed similar qualitative (but not quantitative) pre-
contrast SWI venography findings; 2) second, by quanti-
tatively associating VVV with the presence or absence of
CCSVI, we found significantly increased pre-contrast
DFV, decreased ATVV and ATVV of veins with a dia-
meter < .3 mm, and a trend for decreased VIF in sub-
jects presenting with CCSVI; 3) third, MS patients with
Table 2 Scan-rescan reproducibility in 5 multiple sclerosis
patients and 5 healthy controls who underwent pre- and
post-contrast susceptibility-weighted imaging scan one
week apart.
Pre-contrast
SWI
ICC
Post-contrast
SWI
ICC
ATVV for all vein sizes 0.891 < .001 0.912 < .001
ATVV with diameter < .3 mm 0.812 .002 0.825 .001
ATVV with diameter < .3-.6 mm 0.888 < .001 0.907 < .001
ATVV with diameter < .6-9 mm 0.923 < .001 0.941 < .001
ATVV with diameter > .9 mm 0.935 < .001 0.942 < .001
Venous intracranial fraction 0.791 .002 0.815 .001
Average distance from vein 0.738 .003 0.777 .002
ATVV - apparent total venous volume; mm - millimeters
Intraclass correlation coefficient and p values are presented.
Table 3 Presence and severity of CCSVI in multiple
sclerosis patients and healthy controls.
MS
(n = 59)
HC
(n = 33)
p RR
(n = 41)
SP
(n = 18)
p
No CCSVI, n (%) 12 (21.3) 27 (81.8) < .0001 11 (26.8) 1 (5.6) NS
CCSVI, n (%) 47 (79.7) 6 (18.2) 30 (73.2) 17 (94.4)
VHISS, mean (SD) 4.9 (3.1) 1.5 (1.6) < .0001 5.2 (3.6) 4.2 (1.4) NS
CCSVI - chronic cerebrospinal venous insufficiency; VHISS - venous
hemodynamic insufficiency score; MS - Multiple Sclerosis; HC - Healthy
Controls; RR - Relapsing-Remitting; SP - Secondary Progressive; NS - non
significant
The differences between the study groups were tested using Fisher’s exact
tests and the Mann-Whitney rank sum test. All subjects had the 5 venous
hemodynamic criteria correctly assessed.
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higher number of venous stenoses, indicative of CCSVI
severity, showed significantly decreased VVV in the
brain parenchyma on both pre- and post-contrast SWI.
The pathogenesis of these findings has to be further
investigated, but they suggest that decreased venous vas-
culature in brain parenchyma of MS patients is strongly
related to presence and severity of CCSVI. These find-
ings are important for better understanding of the MS
pathogenesis, and the current findings support results of
two previous pilot hemodynamic imaging studies (using
PWI and CSF flow measurement) that showed that drai-
nage problems in patients with MS are associated with
presence and severity of CCSVI [18,19]. By quantita-
tively measuring the most important drainage pathway
from brain parenchyma to the periphery, which consists
of the veins themselves, we are confirming and extend-
ing the validity of these previous preliminary findings.
When MS patients’ subtypes were compared, the asso-
ciation between the severity of CCSVI and altered pre-
and post-contrast SWI VVV was stronger in RR than in
SPMS patients, and RRMS patients also presented with
a trend for more altered pre- and post-contrast SWI
VVV compared to the SP group. The significance of
these findings is unclear and should be further explored;
however, it could indicate that VVV changes may occur
very early on in the MS disease process.
This study did not explore the relationship between
SWI-VVV and markers of inflammation and demyelina-
tion in patients with MS from the earliest clinical stages.
It could be that the reduced venous visibility in brain
parenchyma of MS patients, and consequently decreased
venous vasculature, is secondary to the presence and
severity of inflammatory and demyelinating lesions that
are accumulating over time in MS patients. Further stu-
dies using conventional and non-conventional MRI
measures are needed to determine how presence and
severity of intrinsic lesion damage relates to changes in
venous vasculature. Therefore, the pathogenetic role of
our VVV findings should be interpreted with caution.
The automated vein extraction segmentation approach
we have developed greatly diminishes the impact of
individual operators. The algorithm was based on the
vesselness filter described by Sato et al., [26], as this was
proven by the authors to be stable and highly reproduci-
ble. The intrinsic advantage of this approach lies in its
multi-dimensionality, allowing for the segmentation of
Table 4 Quantitative brain parenchyma venous vascular assessment in multiple sclerosis patients and healthy controls
on pre- and post-contrast susceptibility-weighted images.
MS (n = 59)
Pre-contrast
Mean (SD)
MS (n = 48)
Post-contrast
Mean (SD)
HC (n = 33)
Pre-contrast
Mean (SD)
HC (n = 7)
Post-contrast
Mean (SD)
p-valuea p-valueb p-valuec p-valued
ATVV for all vein diameters 66.9 (16.6) 68.9 (15.1) 82.9 (17.4) 91.6 (18.1) < .0001 < .0001 NS .01
ATVV with diameter < .3 mm 45 (10) 48.9 (7.9) 53.8 (10.2) 61.3(7.7) < .0001 < .0001 NS .01
ATVV with diameter .3-.6 mm 15.5 (4.4) 16.3 (4.6) 17.4 (4.7) 21.2 (5.2) .068 .046 NS .018
ATVV with diameter .6-.9 mm 4.5 (1.8) 4.5 (2) 4.9 (2) 5.3 (2) NS NS NS .044
ATVV with diamater > .9 mm 1.9 (0.9) 1.9 (1.2) 2.1 (0.9) 2.3 (0.9) NS NS NS NS
Venous intracranial fraction 0.061
(0.02)
0.062 (0.01) 0.067 (0.01) 0.069 (0.01) .049 .05 NS NS
Average distance from vein 1.24 (0.2) 1.23 (0.4) 1 (0.1) 0.94 (0.1) < .0001 < .0001 NS .018
RR (n = 41)
Pre-contrast
Mean (SD)
RR (n = 32)
Post-contrast
Mean (SD)
SP (n = 18)
Pre-contrast
Mean (SD)
SP (n = 9)
Post-contrast
Mean (SD)
p-valuee p-valuef
ATVV for all vein diameters 64.5 (18.7) 66.5 (17.2) 72.4 (8.3) 74.2 (6.2) .06 NS
ATVV with diameter < .3 mm 43.4 (11.1) 47.7 (8.5) 48.6 (7.1) 51.5 (5.9) .046 NS
ATVV with diameter .3-.6 mm 14.9 (5) 15.4 (5.2) 16.9 (2.1) 18.3 (2) NS .048
ATVV with diameter .6-.9 mm 4.2 (2.1) 4.2 (2.2) 5.2 (0.6) 5.2 (0.4) NS NS
ATVV with diamater > .9 mm 1.8 (1.1) 1.7 (1.4) 2.3 (0.5) 2.1 (0.4) NS NS
Venous intracranial fraction 0.058
(0.02)
0.059
(0.01)
0.068 (0.008) 0.068
(0.008)
.025 .052
Average distance from vein 1.26 (0.2) 1.29 (0.4) 1.22 (0.2) 1.23 (0.2) NS NS
MS - Multiple Sclerosis; HC - Healthy Controls; RR - Relapsing-Remitting; SP - Secondary Progressive; NS - non significant; ATVV - apparent total venous volume
ATVV values are in milliliters and average distance from vein in millimeters.
p valuea - represents pre-contrast SWI VVV measure differences between MS patients and HC, p valueb - represents differences between MS patients post-
contrast and HC pre-contrast SWI VVV measures, p valuec - represents pre- and post-contrast SWI VVV measure differences in MS patients, p valued - represents
pre- and post-contrast SWI VVV measure differences in HC controls, p valuee represents pre-contrast SWI VVV measure differences between RR and SP patients, p
valuef - represents post-contrast SWI VVV measure differences between RR and SP patients.
The differences between the study groups were tested using the Mann-Whitney rank sum test. The differences between pre-contrast and post-contrast SWI VVV
measures in the same individuals were tested using the Wilcoxon signed rank test.
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vessels of different sizes, the ability to recover continuity
of the structures despite higher local noise levels, and
most of all the fact that it is not based on absolute sig-
nal intensity (zero order information) but rather on
intensity gradients surrounding each voxel (second
order information), giving sensitivity to the shape of the
structures. The vesselness filter is integrated into the
ITK library (Insight Segmentation and Registration
Toolkit, http://www.itk.org/) and has been applied to
vessel segmentation on various imaging techniques,
including MRI, computerized tomography and optical
computerized tomography.
The scan-rescan experiment data showed that SWI
venography VVV indices we measured are highly repro-
ducible (Table 2). As expected, post-contrast SWI VVV
measures showed slightly better reproducibility results
than pre-contrast measures. Of all different vein dia-
meter ATVV measurements we performed, the veins
with larger diameter (> .3 mm) showed better reprodu-
cibility than those < .3 mm. This is expected, as the seg-
mentation outcome of veins < .3 mm will be most
influenced by image quality, movement-related partial
volume effects and image processing steps. These may
be related to different parameters, including image con-
trast-to-noise ratio, unwrapping of phase images, filter
characteristics (tuning parameters, threshold) of the
Hessian filter, motion artifacts, and change in SNR.
However, we inspected all segmentation output of the
images visually. In addition, our reproducibility analysis
did not show that the potential change of these imaging
parameters affected the reproducibility of results over
one week. On the other hand, VIF and DFV displayed a
reduced reproducibility. For the VIF, the reason most
likely lies in the intrinsic uncertainty in the estimation
of the intra-cranial volume, which is used to normalize
the VVV across subjects. For the DFV instead, reduced
reproducibility is the effect of the enhanced vein visibi-
lity which characterizes the mIP maps.
SWI is very sensitive in detecting signals from sub-
stances with magnetic susceptibilities that are different
from that of their neighbors. Consequently, SWI is able
to detect tissue iron in the form of ferritin, hemosiderin
and deoxyhemoglobin, [25,33,34] and is sensitive to the
visualization of small veins in the brain [10]. SWI veno-
graphy allows detailed visualization of cerebral veins in
the brain parenchyma without the use of an exogenous
contrast agent [9]. This is possible by exploiting the dif-
ference in magnetic susceptibility properties between
oxygenated and deoxygenated hemoglobin. The abun-
dance of the paramagnetic deoxyhemoglobin molecule
in the venous blood results in increased local magnetic
field inhomogeneity, which in turn leads to spin dephas-
ing and signal loss on SWI venography, resulting in
Table 5 Quantitative brain parenchyma venous vascular
assessment in multiple sclerosis patients and healthy
controls, according to CCSVI status on pre-contrast
susceptibility-weighted images.
Total
CCSVI
(n = 53)
Mean (SD)
Total No
CCSVI
(n = 39)
Mean (SD)
p-
value
ATVV for all vein diameters (ml) 67.2 (17.8) 78.3 (16.6) .003
ATVV with diameter < 0.3 mm
(ml)
45.1 (11) 51 (9.4) .003
Venous intracranial fraction 0.059 (0.02) 0.067 (0.01) .044
Average distance from vein
(mm)
1.25 (0.2) 1.1 (0.1) < .0001
MS CCSVI
(n = 47)
MS No CCSVI
(n = 12)
ATVV for all vein diameters (ml) 65.1 (17.1) 70 (8) NS
ATVV with diameter < 0.3 mm
(ml)
44 (10.8) 47 (4.5) NS
Venous intracranial fraction 0.059 (0.02) 0.066 (0.01) .084
Average distance from vein
(mm)
1.29 (0.2) 1.08 (0.02) .01
CCSVI - chronic cerebrospinal venous insufficiency; MS - Multiple Sclerosis; NS
- non significant; ATVV - apparent total venous volume; ml - milliliters; mm -
millimeters
The differences between the study groups were tested using the Mann-
Whitney rank sum test.
Table 6 Relationship between the venous hemodynamic
severity score (VHISS) and quantitative brain
parenchyma venous vasculature in multiple sclerosis
patients on pre-and post-contrast susceptibility-weighted
images.
Pre-contrast MS
(n = 59)
RR
(n = 41)
SP
(n = 18)
r p r p r p
ATVV for all vein diameters
(ml)
-0.54 < .0001 -0.7 < .0001 -0.17 .500
ATVV with diameter < 0.3
mm (ml)
-0.52 < .0001 -0.67 < .0001 -0.24 .340
Venous intracranial fraction -0.54 < .0001 -0.67 < .0001 -0.12 .653
Average distance from vein
(mm)
0.64 < .0001 0.73 < .0001 0.21 .413
Post-contrast MS
(n = 48)
RR
(n = 36)
SP
(n = 12)
r p r p r p
ATVV for all vein diameters
(ml)
-0.46 < .0001 -0.47 < .0001 -0.23 .425
ATVV with diameter < 0.3
mm (ml)
-0.48 < .0001 -0.53 < .0001 -0.14 .722
Venous intracranial fraction -0.57 < .0001 -0.6 < .0001 -0.28 .354
Average distance from vein
(mm)
0.62 < .0001 0.72 < .0001 0.26 .324
MS - Multiple Sclerosis; RR - Relapsing-Remitting; SP - Secondary Progressive;
ATVV - apparent total venous volume;
The relationship between VHISS and quantitative brain parenchyma venous
was explored using the Spearman rank correlation coefficient.
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decreased VVV [10]. One of the key aims of this study
was to address whether the SWI venography VVV dif-
ferences between MS patients and HC are only a result
of decreased oxygen utilization in MS patients (with
correspondent decreased levels of venous deoxyhemo-
globin), as previously proposed, [10] or if there were
also morphological changes in the small veins that
became atrophic and disappeared due to the MS disease
process, possibly leading to permanent decrease of signal
on SWI. Contrast-enhanced SWI significantly increases
the visualization of number and volume of signal
hypointensities on SWI venography [28,29] in T2 lesions
and in normal appearing WM (Figure 4), [30] and may
be an additional means of investigating whether SWI
venography differences between MS patients and HC
are due only to hypometabolic status or whether mor-
phological changes of veins may be taking place in MS
patients. 81.4% of the MS patients and 21.2% of HC
included in this study underwent both pre- and post-
contrast SWI sequence in order to further elucidate this
important question. We demonstrated a very similar
decrease in brain parenchyma VVV on pre- and post-
contrast SWI parameters we examined in MS patients,
but significantly increased ATVV and ATVV of veins
with a diameter < .3 mm in HC was found, as expected
(Table 4). The reduction of vascular visibility on pre-
contrast SWI between MS patients and HC was pre-
viously observed and attributed to hypometabolic status
in brain parenchyma of MS patients [10]. However, the
pre- and post-contrast SWI venography experiment per-
formed in the present study further extends understand-
ing of this phenomenon and suggests that the reduced
VVV in MS may be a combination of two main effects -
reduced metabolism and morphological changes of the
venous vasculature. Further cross-sectional and longitu-
dinal studies are needed to better elucidate this phe-
nomenon. Subtraction technique approaches may be
useful for detecting whether the loss of signal occurs in
the same regions between pre- and post-contrast SWI
venography. In addition, region-specific analysis may
Figure 5 Scatter plots of the pre-contrast SWI venography measures and severity of the CCSVI (VHISS) in multiple sclerosis patients.
Zivadinov et al. BMC Neurology 2011, 11:128
http://www.biomedcentral.com/1471-2377/11/128
Page 12 of 15
shed light regarding key areas that are involved. Visual
analysis performed in this study suggests that cortical
and deep WM/GM regions may be the most affected
(Figure 3).
A hypoxia-like condition has been evidenced in
patients with MS [35,36]. It has been shown that hypo-
perfusion of the brain parenchyma in MS patients may
precede disease onset [37,38]. Abnormal perfusion pat-
terns within normal appearing WM and GM were
demonstrated in MS patients [38-41]. Chronic inflam-
matory events related to local blood congestion and sec-
ondary hyperemia of the brain parenchyma are
proposed as a cause of these hemodynamic abnormal-
ities detected on perfusion MRI in patients with MS
[39,42,43]. Whether reduced perfusion of the WM and
GM in MS patients is a sign of vascular pathology,
decreased metabolic demand [36] or precipitated hemo-
dynamic changes in the extra-cranial venous pathways
[17] is not clear at this time. We recently reported in a
pilot study a significant relationship between the severity
of CCSVI and hypoperfusion in the brain parenchyma of
16 MS patients, but not in 8 healthy controls [17].
One of the key findings in this study is that MS
patients presenting with CCSVI (and with increased
severity of CCSVI, as measured by VHISS) showed
decreased pre- and post-contrast VVV in brain parench-
yma on SWI venography. These findings confirm results
of earlier studies, [38-42] all of which observed signifi-
cantly lower perfusion in the brain parenchyma of MS
patients compared with controls. It could be hypothe-
sized that decreased venous outflow from the brain par-
enchyma to the periphery would lead to increased
intracranial pressure and subsequent venous stasis, espe-
cially of the small vein vasculature. Venous pressure was
not measured in the current study; however, a recent
study showed no increased intracranial venous pressure
in MS patients [44]. Nevertheless, increased venous
pressure in the subarachnoid space of MS patients can-
not be excluded at this time. Several authors have
hypothesized that reduced venous drainage outflow in
MS may increase intra-capillary oncotic pressure, which
would lead to decreased capillary permeability toward
the extra cellular compartment and consequent intra-tis-
sue accumulation of toxic metabolites [12,45]. In the
present study, the association between presence and
severity of CCSVI was particularly strong with VVV
indices of small veins. We showed that there was a
trend for differences between patients and controls for
veins with a diameter < .6 mm. Hypoxia arising from
stasis in the veins might therefore induce morphological
changes which could result in occlusion and atrophy of
these veins. Therefore, the most plausible explanation of
our findings would be that reduced outflow from small
vessels to the periphery–independent of whether it is
primary or secondary to CCSVI or inflammatory and
demyelinating lesions–leads to destruction of smaller
veins and consequent loss of signal visibility on SWI
venography. The pathogenesis of this process remains
unanswered at this time and should be explored
together with dynamic of regional lesion accumulation
over time.
This loss of vasculature suggests that rerouting of the
intracranial venous blood flow is probably taking place.
If CCSVI is secondary to various vascular, infective and
inflammatory processes (this hypothesis could explain
the presence of CCSVI in HC), then the tendency to be
chronic in its development may help explain the tem-
poral dissociation between the loss of the VVV and no
development of intracranial hypertension. In that con-
text, hemodynamic compensatory mechanisms may play
a key role. One such mechanism could relate to the
development of extra-cranial collateral circulation
[14,16] or altered CSF dynamics [17] that would com-
pensate for altered primary outflow pathways.
Some recent reports have presented evidence against
the CCSVI hypothesis in MS using Doppler and MRV
assessments [46-51]. The conflicting reports of CCSVI-
related venous abnormality prevalence findings between
different studies using non-invasive and invasive imaging
techniques emphasize the urgent need for better under-
standing of these anomalies. It is also important to place
CCSVI in the context of other known associations in
MS, with the most well established MS risk factors and
clinical and MRI outcomes. The current study provides
important evidence that extra-cranial venous abnormal-
ities may be related to intra-cranial brain parenchyma
reduced venous visibility. The dynamic of these findings
should be further explored.
There are a number of limitations to the present
study. One relates to the use of the proposed CCSVI
criteria, [14] which could be insufficient to adequately
describe the cerebral venous outflow due to the lack of
assessment of functional data on blood flow velocity and
blood volume flow [46]. Evaluation of blood flow velo-
city and blood volume flow may offer more complete
status of the cerebral venous outflow in relation to
decreased brain parenchyma SWI VVV in patients with
MS. Another limit of the study is related to its cross-
sectional design and to the relatively small number of
subjects studied, especially of HC and MS patients at
the early stage of the disease. Due to the nature of SWI
phase imaging and associated “blooming” effects, our
measurements of venous volume are inherently relative
rather than absolute. Finally, the validation of our VVV
method should be performed against either simulations
or phantom measurements.
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Conclusion
In conclusion, the current study provides an initial step
in better understanding of how decreased venous vascu-
lature in brain parenchyma of MS patients may be
related to the pathogenesis of MS. Further studies need
to confirm and elucidate our findings.
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